A Review of Consent Practices and Perspectives for Pharmacogenetic Testing

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2016 Aug 18

PMID 27533720

Citations 10

Authors

Susanne B Haga

Rachel Mills

Affiliations

Soon will be listed here.

Abstract

Aim: We aimed to understand consent practices for pharmacogenetic (PGx) testing.

Methods: We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing.

Results: Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx testing. We identified 35 companies offering PGx testing and were able to confirm consent practices for 22 of those. We found a range of variability in the consent practices regarding the consent approach and information disclosed.

Conclusion: Variability in the consent practices among laboratories offering PGx testing mirrors the ambiguous practices and recommendations reported in the literature. Establishing a minimal set of information to be disclosed to patients may help address the disparities in consent practice.

Citing Articles

Biobanks in chronic disease management: A comprehensive review of strategies, challenges, and future directions.

Xu W, Liang X, Chen L, Hong W, Hu X Heliyon. 2024; 10(11):e32063.

PMID: 38868047 PMC: 11168399. DOI: 10.1016/j.heliyon.2024.e32063.

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.

Pereira L, Haidar C, Haga S, Cisler A, Hall A, Shukla S Front Pharmacol. 2024; 15:1355412.

PMID: 38410134 PMC: 10895424. DOI: 10.3389/fphar.2024.1355412.

Mental Health Prescribers' Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region.

Aboelbaha S, Zolezzi M, Abdallah O, Eltorki Y Pharmgenomics Pers Med. 2023; 16:503-518.

PMID: 37274729 PMC: 10239256. DOI: 10.2147/PGPM.S410240.

How to Implement a Pharmacogenetics Service at your Institution.

Cicali E, Lemke L, Al Alshaykh H, Nguyen K, Cavallari L, Wiisanen K J Am Coll Clin Pharm. 2023; 5(11):1161-1175.

PMID: 36589694 PMC: 9799247. DOI: 10.1002/jac5.1699.

Experiences and practices of key research team members in obtaining informed consent for pharmacogenetic research among people living with HIV: a qualitative study.

Nabukenya S, Ochieng J, Kaawa-Mafigiri D, Munabi I, Nakigudde J, Nakwagala F Res Ethics. 2022; 18(3):193-209.

PMID: 36213304 PMC: 9536131. DOI: 10.1177/17470161221076974.

References

Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W . Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics. 2005; 7(1):49-59. DOI: 10.2217/14622416.7.1.49. View

Stanek E, Sanders C, Taber K, Khalid M, Patel A, Verbrugge R . Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012; 91(3):450-8. DOI: 10.1038/clpt.2011.306. View

Green R, Berg J, Grody W, Kalia S, Korf B, Martin C . ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15(7):565-74. PMC: 3727274. DOI: 10.1038/gim.2013.73. View

Romeo-Malanda S, Nicol D . Pharmacogenetic testing: legal considerations for consent, privacy and disclosure. Per Med. 2018; 5(2):155-161. DOI: 10.2217/17410541.5.2.155. View

Hoop J, Roberts L, Green Hammond K, Cox N . Psychiatrists' attitudes regarding genetic testing and patient safeguards: a preliminary study. Genet Test. 2008; 12(2):245-52. DOI: 10.1089/gte.2007.0097. View

Hedgecoe A . Context, ethics and pharmacogenetics. Stud Hist Philos Biol Biomed Sci. 2006; 37(3):566-82. DOI: 10.1016/j.shpsc.2006.06.003. View

Howard H, Joly Y, Avard D, Laplante N, Phillips M, Tardif J . Informed consent in the context of pharmacogenomic research: ethical considerations. Pharmacogenomics J. 2011; 11(3):155-61. DOI: 10.1038/tpj.2011.11. View

Platt J, Cox R, Enns G . Points to consider in the clinical use of NGS panels for mitochondrial disease: an analysis of gene inclusion and consent forms. J Genet Couns. 2014; 23(4):594-603. DOI: 10.1007/s10897-013-9683-2. View

Rieger P, Pentz R . Genetic testing and informed consent. Semin Oncol Nurs. 1999; 15(2):104-15. DOI: 10.1016/s0749-2081(99)80068-0. View

10.

Warner A, Bhathena A, Gilardi S, Mohr D, Leong D, Bienfait K . Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin Pharmacol Ther. 2011; 89(4):529-36. DOI: 10.1038/clpt.2010.305. View

11.

Woelderink A, Ibarreta D, Hopkins M, Rodriguez-Cerezo E . The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 2005; 6(1):3-7. DOI: 10.1038/sj.tpj.6500341. View

12.

Zhang S, Bruce C, Hayden M, Rieder M . Public perceptions of pharmacogenetics. Pediatrics. 2014; 133(5):e1258-67. DOI: 10.1542/peds.2013-1416. View

13.

Reiff M, Ross K, Mulchandani S, Propert K, Pyeritz R, Spinner N . Physicians' perspectives on the uncertainties and implications of chromosomal microarray testing of children and families. Clin Genet. 2012; 83(1):23-30. PMC: 3527693. DOI: 10.1111/cge.12004. View

14.

Mills R, Voora D, Peyser B, Haga S . Delivering pharmacogenetic testing in a primary care setting. Pharmgenomics Pers Med. 2013; 6:105-12. PMC: 3791676. DOI: 10.2147/PGPM.S50598. View

15.

Wertz D . Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J. 2003; 3(4):194-6. DOI: 10.1038/sj.tpj.6500188. View

16.

Berliner J, Fay A, Cummings S, Burnett B, Tillmanns T . NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2012; 22(2):155-63. DOI: 10.1007/s10897-012-9547-1. View

17.

Lucassen A, Hall A . Consent and confidentiality in clinical genetic practice: guidance on genetic testing and sharing genetic information. Clin Med (Lond). 2012; 12(1):5-6. PMC: 4953419. DOI: 10.7861/clinmedicine.12-1-5. View

18.

Moran C, Thornburg C, Barfield R . Ethical considerations for pharmacogenomic testing in pediatric clinical care and research. Pharmacogenomics. 2011; 12(6):889-95. PMC: 3164260. DOI: 10.2217/pgs.10.216. View

19.

Buchanan A, Califano A, Kahn J, McPherson E, Robertson J, Brody B . Pharmacogenetics: ethical issues and policy options. Kennedy Inst Ethics J. 2002; 12(1):1-15. DOI: 10.1353/ken.2002.0001. View

20.

Jackson L, Goldsmith L, Skirton H . Guidance for patients considering direct-to-consumer genetic testing and health professionals involved in their care: development of a practical decision tool. Fam Pract. 2014; 31(3):341-8. DOI: 10.1093/fampra/cmt087. View